Mark J. Soloski

Pilot study of psilocybin in patients with post-treatment lyme disease

Scientific Reports February 25, 2026 Albert Garcia‐romeu, Gideon P. Naudé, Alison W. Rebman et al. 2 citations

Abstract Lyme disease, caused by the bacterium Borrelia burgdorferi , is the most common vector-borne disease in the United States and Europe. Although antibiotics effectively treat most cases, an estimated 10–20% of patients develop post-treatment Lyme disease (PTLD), a chronic syndrome marked by fatigue, pain, cognitive difficulties, mood disturbance, and reduced quality of life. There are no...